Evidence map›Paper›PMID 10914554›Full record

ArticleLeukemia2000

The SH2 domain-containing protein tyrosine phosphatase SHP-1 is induced by granulocyte colony-stimulating factor (G-CSF) and modulates signaling from the G-CSF receptor.

A C Ward, S P Oomen, L Smith, J Gits, D van Leeuwen, A A Soede-Bobok, C A Erpelinck-Verschueren, T Yi, I P Touw

Abstract read
PubMed Publisher
In one paragraph

Article in Leukemia, 2000. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
1.8field-weighted citation impact, top 15% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 41 citations in OpenAlex.

  1. Article
  2. Review
  3. Review
  4. Shp1 function in myeloid cells.Journal of leukocyte biology · 2017
    Review
  5. Article
  6. Review
  7. Review
  8. Article
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 4 institutions in 3 countries.

A C WardInstitute of Hematology, Erasmus University Rotterdam, The Netherlands.
S P Oomen
L Smith
J Gits
D van Leeuwen
A A Soede-Bobok
C A Erpelinck-Verschueren
T Yi
I P Touw
Erasmus University Rotterdam · NLRotterdam University of Applied Sciences · NLCleveland Clinic · USThe University of Queensland · AU

Funding

SHP-1 REGULATION OF THE KU SIGNALING PATHWAYR01GM058893 · NIGMS · CLEVELAND CLINIC FOUNDATION · PI YI, TAOLIN · 1999 to 2003
$625k
SHP-1/TYK2 INTERACTION AND ITS DEFECT IN FHLH DISEASER01CA079891 · NCI · CLEVELAND CLINIC FOUNDATION · PI YI, TAOLIN · 1999 to 2001
$270k
NCI NIH HHS CA79891NIGMS NIH HHS GM58893
6 · The paper itself

Abstract

The SH2 domain-containing protein tyrosine phosphatase SHP-1 is expressed widely in the hematopoietic system. SHP-1 has been shown to negatively control signal transduction from many cytokine receptors by direct docking to either the receptor itself, or to members of the Jak family of tyrosine kinases which are themselves part of the receptor complex. Motheaten and viable motheaten mice, which are deficient in SHP-1, have increased myelopoiesis and show an accumulation of morphologically and phenotypically immature granulocytes, suggesting a role for SHP-1 in granulocytic differentiation. Here, we report that SHP-1 protein levels are up-regulated during the granulocyte colony-stimulating factor (G-CSF)-mediated granulocytic differentiation of myeloid 32D cells. Enforced expression of SHP-1 in these cells leads to decreased proliferation and enhanced differentiation, while introduction of a catalytically inactive mutant produces increased proliferation and results in a delay of differentiation. In vitro binding revealed that the SH2 domains of SHP-1 are unable to associate directly with tyrosine-phosphorylated G-CSF receptor (G-CSF-R). Furthermore, over-expression of SHP-1 in Ba/F3 cells expressing a G-CSF-R mutant lacking all cytoplasmic tyrosines also inhibited proliferation. Together, these data suggest that SHP-1 directly modulates G-CSF-mediated responses in hematopoietic cells via a mechanism that does not require docking to the activated G-CSF-R.

Indexed as

AnimalsCell DifferentiationCell DivisionGene Expression RegulationGene Expression Regulation, LeukemicGranulocyte Colony-Stimulating FactorHematopoietic Stem CellsHumansInterleukin-3Intracellular Signaling Peptides and ProteinsMiceNeoplasm ProteinsPrecursor B-Cell Lymphoblastic Leukemia-LymphomaProtein Tyrosine Phosphatase, Non-Receptor Type 11Protein Tyrosine Phosphatase, Non-Receptor Type 6Protein Tyrosine PhosphatasesGranulocyte Colony-Stimulating FactorInterleukin-3Intracellular Signaling Peptides and ProteinsNeoplasm ProteinsProtein Tyrosine Phosphatase, Non-Receptor Type 11Protein Tyrosine Phosphatase, Non-Receptor Type 6Protein Tyrosine PhosphatasesPTPN11 protein, humanPtpn11 protein, mousePTPN6 protein, humanPtpn6 protein, mouseReceptors, Granulocyte Colony-Stimulating FactorRecombinant Fusion ProteinsSH2 Domain-Containing Protein Tyrosine Phosphatases

Identifiers

PMID10914554
OpenAlexW2324906471

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.